CalciMedica (CALC) 10-Q2022 Q1 Quarterly report

Filed: 11 May 22, 6:28pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AAV, Abbott, Amgen, analog, analytical, analyze, appellate, Apr, Ariad, artificial, ASC, ASU, atrophy, banc, bid, Biosafety, BLA, borrow, borrowing, BPCIA, calendar, Carolina, caution, cautioned, CBER, Cellular, center, cGMP, Chapel, Cir, Circuit, clouding, Codification, collateralized, complement, consecutive, copy, cornea, Ct, cyclic, dance, delisted, delisting, discretionary, disorder, dollar, donut, dosage, Eli, en, encoding, encompassed, Enzo, equal, expedient, FASB, faster, Fed, field, fourth, gene, genetic, geographic, Gilead, grow, guanosine, hereditary, Hill, holdback, hole, Idenix, identification, immoral, Immunex, immunologic, implant, implicit, incremental, inflation, intangible, intelligence, intercompany, learn, lengthen, lengthier, lessee, Lilly, LLC, lysosomal, maximum, Med, medicine, Molecular, monophosphate, monthly, MPS, NaN, North, ODD, Omicron, orphan, OTAT, outflow, pigmentosa, pipeline, plural, PRV, RainBio, reaction, ready, recessionary, recognition, recombinant, regain, rescue, restoring, retrospective, RP, RPDD, Sandoz, Sanofi, scarcity, screening, Simplifying, subgroup, subsidiary, substituted, substitution, Summary, Sys, talent, thereto, thirty, timolol, tolerable, Topic, traditional, twelve, UNC, unchanged, undue, unethical, unsafe, upcoming, USPTO, variable, versa, vice, voucher, weight, wholly, Wyeth

Removed: adjustment, agreed, allocated, assessing, cautionary, contingently, detachable, elimination, exercisable, fact, freestanding, harbor, implied, inclusive, instrument, intravitreally, investigative, legally, met, methodology, nondeductible, notified, occurrence, outpatient, publicly, readout, redeemable, remeasured, SAE, separately, tranche, translation

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CALC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Graybug Vision, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 11, 2022			By:	/s/ Robert S. Breuil
				Robert S. Breuil
				Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)